Reports have said that Beijing is speaking out against the US court that recently ordered two Chinese manufacturers of Vitamin C to pay $162 million in damages for price-fixing. The US court is now accused of infringing on Beijing’s sovereignty. A spokesman for China’s Ministry of Commerce spoke out against the US court at a press conference, arguing that the ruling was “unfair and improper” and that the accused companies were simply complying with the Chinese government’s requirements. Last week a federal court in New York ordered that North China Pharmaceutical Group Corp and one of its affiliates to pay the fine after the defendants argued that the “price-fixing cartel” found to have existed by the jury was the result of Chinese government decisions. The fines were trebled by the judge.
Featured News
NBA Teams Up With US Regulator on Prediction Markets
Oct 27, 2026 by
CPI
Intesa Wins ECB Approval for $36 Billion Monte dei Paschi Takeover
Oct 27, 2026 by
CPI
PayPal, Revolut Weigh In as UK Targets Apple’s Tap-to-Pay Rules
Oct 27, 2026 by
CPI
Heineken Ordered to Pay $124 Million in Greek Antitrust Case
Oct 27, 2026 by
CPI
FTC Raises Antitrust Concerns Over Cintas’ $5.5 Billion Deal
Oct 27, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Exclusive Dealing
Oct 25, 2026 by
CPI
Exclusive Dealing Without Exclusivity: Screening Contracts, Loyalty Rebates, and the Limits of Antitrust Tests
Oct 25, 2026 by
David Martimort & Jérôme Pouyet
When Competition for Exclusivity Raises Prices: Rebates, Pricing Rules, and the Insulin Puzzle
Oct 25, 2026 by
Daniel P. O’Brien & Greg Shaffer
Why Leaving the Door Open Can Be (Much) Worse Than Closing It: Share-Based Requirements, Buyer-Specific Costs, and Foreclosure
Oct 25, 2026 by
Zhijun Chen & Greg Shaffer
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI